Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 17, 2025

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma
09:52

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma

Published on: June 6, 2025

126

GP100 expression is variable in intensity in melanoma.

Jacqueline E Mann1, Nitzan Hasson1, David G Su2

  • 1Division of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA.

Cancer Immunology, Immunotherapy : CII
|August 6, 2024
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis of granulomatous inflammation in thoracic small biopsies and fine needle aspiration specimens: a multi-institutional study.

Journal of the American Society of Cytopathology·2026
Same author

Development of [<sup>111</sup>In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages.

Molecular pharmaceutics·2026
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Advances in Cancer Immunotherapy for Solid Tumors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Clinicopathologic characterization of renal tumors with Folliculin (FLCN) biallelic inactivation.

Virchows Archiv : an international journal of pathology·2026
Same author

Leading Consortiums from the Ground Up: Leveraging Trainee Collaboration to Create Consensus Guidelines.

Annals of surgical oncology·2026
Same journal

NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Integrative analysis of small cell carcinoma of the uterine cervix reveals its heterogeneity and provides novel predictive markers.

Cancer immunology, immunotherapy : CII·2026
Same journal

EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses.

Cancer immunology, immunotherapy : CII·2026
Same journal

Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy.

Cancer immunology, immunotherapy : CII·2026
Same journal

Transcriptomic landscape of peripheral T cells following CAR-T cell therapy in diffuse large B cell lymphoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

HMGB1 ubiquitination inhibition and extracellular secretion, mediated by m<sup>6</sup>A modified-exosomal lncRNA MALAT1, creates a communication between NK92-MI cells and tumor cells to aggravate acute lymphoblastic leukemia.

Cancer immunology, immunotherapy : CII·2026
See all related articles
This summary is machine-generated.

gp100 expression is higher in metastatic melanoma, but intensity varies. This finding is crucial for selecting patients for gp100-targeted therapies like Tebentafusp in cutaneous melanoma clinical trials.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • gp100 is a target for melanoma therapies due to its specificity in melanocytes.
  • Tebentafusp, a gp100-targeting bispecific antibody, shows promise in uveal melanoma and is being studied in cutaneous melanoma.
  • Limited data exists on gp100 expression levels in advanced cutaneous melanoma.

Purpose of the Study:

  • To investigate the extent and intensity of gp100 expression in a large cohort of primary and metastatic melanomas.
  • To assess the variability of gp100 expression in different melanoma stages.
  • To inform patient selection for gp100-directed therapies.

Main Methods:

  • Immunohistochemistry (IHC) was used to evaluate gp100 expression in primary and metastatic melanoma samples.
Keywords:
Glycoprotein 100ImmTACMelanomaTargeted therapyTebentafusp

More Related Videos

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.5K
Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

20.3K

Related Experiment Videos

Last Updated: Jun 17, 2025

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma
09:52

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma

Published on: June 6, 2025

126
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.5K
Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

20.3K
  • Quantitative immunofluorescence was employed to confirm and quantify gp100 expression variability.
  • Analysis of a large patient cohort provided comprehensive data on gp100 expression patterns.

    • Main Results:

    • gp100 expression was globally higher in metastatic melanoma samples compared to primary.
    • gp100 expression was almost uniformly positive in metastatic melanomas, but with variable intensity.
    • Quantitative immunofluorescence confirmed significant variability in gp100 expression levels.

    Conclusions:

    • gp100 is widely expressed in metastatic melanoma, though expression intensity varies.
    • Understanding gp100 expression levels is critical for optimizing patient selection in clinical trials.
    • Further studies correlating drug activity with gp100 expression levels are warranted to enhance therapeutic efficacy.